Active substances
Paracetamol + Pseudoephedrine
- SFDA 3
- Health Canada 8
- NHS prices 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| ADOL SINUS 325MG-30MG CAPLET | 325,30 mg,mg | Tablet · Oral use | 24 Blister | SAR 10.90 | NCE · OTC | Gulf Pharmaceutical Industries (Julphar) | Valid |
| Fevadol Sinus | 500,30 mg,mg | Tablet · Oral use | 30 Blister | SAR 13.90 | Generic · OTC | SPIMACO ADDWAEIH | Valid |
| PANADOL SINUS CAPLET | 500,30 mg,mg | Tablet · Oral use | 24 Blister | SAR 13.60 | Generic · OTC | Haleon Australia Pty Ltd | Valid |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| CHILDREN'S TYLENOL COLD & STUFFY NOSE | 02229538 | 15 MG / 5 ML; 160 MG / 5 ML | SUSPENSION · ORAL | KENVUE CANADA INC. |
| COLD AND SINUS DAYTIME RELIEF | 02385252 | 500 MG; 30 MG | TABLET · ORAL | VITA HEALTH PRODUCTS INC |
| EXTRA STRENGTH HEAD COLD AND SINUS | 02248646 | 60 MG; 500 MG | TABLET · ORAL | VITA HEALTH PRODUCTS INC |
| EXTRA STRENGTH SINUTAB SINUS DAYTIME | 01938371 | 500 MG; 30 MG | TABLET · ORAL | KENVUE CANADA INC. |
| EXTRA STRENGTH SUDAFED HEAD COLD & SINUS | 02239159 | 500 MG; 60 MG | TABLET · ORAL | KENVUE CANADA INC. |
| EXTRA STRENGTH TYLENOL COLD & SINUS DAYTIME | 02348071 | 30 MG; 500 MG | TABLET · ORAL | KENVUE CANADA INC. |
| EXTRA STRENGTH TYLENOL COLD & SINUS PLUS | 02478110 | 60 MG; 500 MG | TABLET · ORAL | KENVUE CANADA INC. |
| SINUS MEDICATION DAYTIME RELIEF | 02368854 | 30 MG; 500 MG | TABLET · ORAL | VITA HEALTH PRODUCTS INC |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| NHS Drug Tariff | Paracetamol 500mg / Pseudoephedrine hydrochloride 30mg tablets | £5.25 | 15 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Components
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.